Foundayo (orforglipron) is a new once-daily oral GLP-1 receptor agonist developed by Eli Lilly for adults living with obesity or certain adults who are overweight and have weight-related health conditions. The medicine has attracted significant attention because, unlike many injectable GLP-1 treatments, it is available as an oral tablet that can be taken once daily without restrictions on the time of day, food, or water intake.
In the United States, the U.S. Food and Drug Administration (FDA) approved Foundayo on April 1, 2026, for weight management in adults with obesity or certain adults with overweight and a weight-related medical condition.
The medicine has also reached the UK market. On August 10, 2026, the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) authorised orforglipron, making the UK the first country in Europe to authorise this GLP-1 tablet for weight management and type 2 diabetes.
This development makes Foundayo particularly relevant to people searching for information about new weight loss pills in the UK, FDA-approved weight loss medications in the U.S., oral GLP-1 medicines, and alternatives to injectable obesity treatments.
Important: Foundayo is a prescription medicine. It should only be used under the supervision of an appropriately qualified healthcare professional. This article is for educational purposes and does not replace medical advice.
What Is Foundayo (Orforglipron)?
Foundayo is the brand name for orforglipron, a once-daily oral GLP-1 receptor agonist developed by Eli Lilly.
Unlike peptide-based GLP-1 medicines, orforglipron is described as a small-molecule, non-peptide GLP-1 receptor agonist. The tablet is designed to activate the GLP-1 receptor and is used alongside a reduced-calorie diet and increased physical activity.
The FDA-approved U.S. indication covers adults with obesity, as well as certain adults with overweight who have at least one weight-related medical problem. The treatment is intended to help reduce excess body weight and maintain weight reduction over the long term.
In the UK, the MHRA has authorised orforglipron for:
- Weight loss and weight maintenance in adults with a BMI of 30 or above.
- Adults with a BMI between 27 and 30 who also have at least one weight-related comorbidity.
- Improving glycaemic control in patients with insufficiently controlled type 2 diabetes.
Is Foundayo Approved in the U.S.?
Yes. Foundayo (orforglipron) was approved by the U.S. FDA on April 1, 2026.
The FDA approved Foundayo to reduce excess body weight and maintain weight reduction in adults with obesity, or adults with overweight who have at least one weight-related comorbid condition, when used with a reduced-calorie diet and increased physical activity.
The FDA’s 2026 novel drug approvals list also records Foundayo (orforglipron) as an approved new molecular entity on April 1, 2026.
The approval is significant because Foundayo provides an oral GLP-1 option for obesity treatment.
Is Orforglipron Approved in the UK?
Yes. Orforglipron (Foundayo) was authorised by the UK’s MHRA on August 10, 2026.
According to the UK government and MHRA, the UK became the first country in Europe to authorise orforglipron for weight management and type 2 diabetes.
This is particularly important for UK readers searching for:
- Foundayo UK
- Orforglipron UK
- Foundayo weight loss pill UK
- New GLP-1 pill UK
- Oral GLP-1 weight loss medicine UK
- Orforglipron availability UK
- Foundayo approval UK
The UK authorisation means that Foundayo is no longer simply an investigational GLP-1 tablet in the UK; it has received regulatory authorisation for specified indications.
However, regulatory authorisation should not automatically be interpreted as NHS availability. Access through the NHS can depend on separate health-technology assessment and prescribing decisions.
Why Is Foundayo Getting So Much Attention?
One of the most important features of Foundayo is its administration.
The medicine is taken once daily by mouth, and the U.S. prescribing information states that it can be taken with or without food. The Lilly information also describes it as having no restrictions on food and water intake.
This may make oral GLP-1 treatment attractive to people who prefer tablets over injections.
The potential advantages include:
1. Oral administration
Foundayo is taken as a tablet rather than an injection.
2. Once-daily dosing
The medicine is taken once each day according to the prescribing instructions.
3. No food-timing requirement
The medicine can be taken with or without food.
4. No water restriction for administration
The Lilly information describes Foundayo as an oral medicine that can be taken without food or water restrictions.
5. Non-peptide GLP-1 molecule
Orforglipron is a small-molecule, non-peptide GLP-1 receptor agonist.
How Much Weight Can You Lose With Foundayo?
The clinical results reported for Foundayo are one of the most important reasons for interest in the medicine.
In the ATTAIN-1 Phase 3 clinical trial, people receiving the highest dose who remained on treatment lost an average of 27.3 pounds (12.4%) after 72 weeks, compared with 2.2 pounds (0.9%) with placebo.
When the analysis included participants regardless of whether they completed the trial treatment, participants taking Foundayo lost an average of 25 pounds (11.1%), compared with 5.3 pounds (2.1%) with placebo.
These results show that orforglipron can produce clinically meaningful weight reduction when combined with lifestyle measures.
However, individual results can vary substantially.
A clinical trial average should not be interpreted as a guarantee that every person taking Foundayo will lose 12.4% of their body weight.
What Did the ATTAIN Clinical Trials Show?
Foundayo’s development was supported by the ATTAIN Phase 3 clinical programme.
According to Lilly, the programme enrolled more than 4,500 people with obesity or overweight across two global registration trials.
ATTAIN-1
ATTAIN-1 was a Phase 3, 72-week, randomised, double-blind, placebo-controlled clinical trial.
It included adults with obesity or overweight plus certain weight-related conditions, including:
- Hypertension
- Dyslipidaemia
- Obstructive sleep apnoea
- Cardiovascular disease
The study did not include people with diabetes and randomised 3,127 participants across multiple countries, including the United States, Brazil, China, India, Japan, South Korea, Puerto Rico, Slovakia, Spain and Taiwan.
The primary objective was to determine whether orforglipron produced greater body-weight reduction than placebo after 72 weeks.
ATTAIN-2
ATTAIN-2 was another 72-week Phase 3 randomised, double-blind, placebo-controlled trial.
This study evaluated adults with obesity or overweight and type 2 diabetes.
More than 1,600 participants were randomised across several countries, including the U.S., Argentina, Australia, Brazil, China, Czechia, Germany, Greece, India, South Korea and Puerto Rico.
Foundayo and Cardiovascular Risk Markers
The ATTAIN programme also reported improvements in several markers associated with cardiovascular risk.
According to the Lilly announcement, Foundayo was associated with reductions in:
- Waist circumference
- Non-HDL cholesterol
- Triglycerides
- Systolic blood pressure
These changes were observed across the studied doses.
However, improvements in risk markers should not be interpreted as proof that Foundayo prevents cardiovascular events unless such an outcome has specifically been demonstrated in an appropriate cardiovascular outcomes trial.
How Do You Take Foundayo?
Foundayo is taken orally once daily.
The U.S. prescribing information states:
- Take it exactly as directed by your healthcare provider.
- Take it once daily.
- It can be taken with or without food.
- Swallow the tablet whole.
- Do not break, crush or chew it.
- Do not take more than one tablet per day.
The U.S. information lists oral tablet strengths of 0.8 mg, 2.5 mg, 5.5 mg, 9 mg, 14.5 mg and 17.2 mg.
Patients should follow the dosing schedule prescribed for them rather than changing the dose themselves.
What Happens If You Miss a Foundayo Dose?
According to the U.S. medication information, if a dose is missed, it should be taken as soon as possible.
However:
Do not take two doses of Foundayo on the same day.
If treatment has been interrupted for 7 or more consecutive days, the patient should contact their healthcare provider for advice about restarting treatment.
Foundayo Side Effects
Like other medicines in the GLP-1 class, Foundayo can cause adverse effects.
The most common side effects reported in the U.S. information include:
- Nausea
- Constipation
- Diarrhoea
- Vomiting
- Indigestion
- Abdominal pain
- Headache
- Abdominal swelling
- Fatigue
- Belching
- Heartburn
- Gas
- Hair loss
Not everyone experiences these effects, and their severity can differ between individuals.
Anyone experiencing persistent or concerning symptoms should speak with their healthcare professional.
Important Safety Warnings for Foundayo
Foundayo carries important safety warnings.
The U.S. prescribing information includes a warning regarding thyroid C-cell tumours. It states that patients with a personal or family history of medullary thyroid carcinoma (MTC), or patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), should not use Foundayo.
Patients should seek medical advice if they develop symptoms such as:
- A lump or swelling in the neck
- Hoarseness
- Difficulty swallowing
- Shortness of breath
Other serious risks described in the medication information include:
- Pancreatitis
- Severe gastrointestinal problems
- Dehydration and kidney problems
- Hypoglycaemia in certain circumstances
- Serious allergic reactions
- Changes in vision in patients with type 2 diabetes
- Gallbladder problems
- Risk associated with food or liquid entering the lungs during certain procedures involving anaesthesia or deep sedation
This is why Foundayo should be considered a prescription treatment rather than an ordinary weight-loss supplement.
Who Should Not Take Foundayo?
According to the U.S. safety information, Foundayo should not be used by people who:
- Have a personal or family history of medullary thyroid carcinoma.
- Have Multiple Endocrine Neoplasia syndrome type 2.
- Have had a serious allergic reaction to orforglipron or its ingredients.
The prescribing information also highlights several situations that require discussion with a healthcare professional, including pregnancy, breastfeeding, pancreatic or kidney problems, severe gastrointestinal problems, diabetic retinopathy and upcoming surgery or procedures involving anaesthesia or deep sedation.
Foundayo and Pregnancy
Pregnancy is an important consideration before starting treatment.
The U.S. medication information states that patients who are pregnant or planning pregnancy should discuss Foundayo with their healthcare provider and notes that Foundayo may harm an unborn baby. Breastfeeding is also not recommended during treatment according to the provided U.S. information.
People who are pregnant, planning pregnancy or breastfeeding should speak with their healthcare professional before using the medicine.
Foundayo and Birth Control Pills
Another important point for patients is the potential interaction with oral contraceptives.
The U.S. medication information states that birth control pills may not work as well while taking Foundayo. It says healthcare providers may recommend another type of birth control for 30 days after starting Foundayo and for 30 days after each dose increase.
Anyone taking an oral contraceptive should discuss this with their healthcare professional before starting treatment.
Can Foundayo Be Taken With Other GLP-1 Medicines?
The U.S. medication information states that Foundayo should not be used with other GLP-1 receptor agonist medicines.
Patients should therefore not combine Foundayo with another GLP-1 medicine on their own.
If someone is already taking a GLP-1 medicine and is considering changing treatments, the transition should be discussed with a qualified healthcare professional.
Is Foundayo Available in the UK?
Yes, orforglipron has been authorised in the UK by the MHRA.
The MHRA announced the authorisation on August 10, 2026, describing the UK as the first country in Europe to authorise orforglipron for weight management and type 2 diabetes.
This is an important distinction for UK readers:
MHRA authorisation does not necessarily mean that every patient can receive the medicine through the NHS.
Regulatory approval and NHS commissioning/access are separate issues.
For UK patients, availability can depend on prescribing pathways, eligibility, private healthcare access and future NHS decisions.
Foundayo UK: Is It Available Through the NHS?
The UK regulatory authorisation should not be confused with automatic NHS availability.
The MHRA is responsible for determining whether medicines meet the required standards for quality, safety and efficacy. Decisions about NHS use involve additional processes.
Therefore, UK readers should distinguish between:
MHRA authorisation → regulatory approval
and
NHS availability → healthcare commissioning and prescribing decisions
This distinction is particularly important when searching for phrases such as “Is Foundayo available on the NHS?” or “Can I get Foundayo on the NHS?”
Patients should check current NHS and NICE information and speak with a healthcare professional rather than relying on social-media claims or online sellers.
Foundayo in the United States: Availability
Following FDA approval, Lilly announced that Foundayo would be made available through LillyDirect, with prescriptions accepted immediately and shipping beginning April 6, 2026, followed by broader availability through U.S. retail pharmacies and telehealth providers.
The company also announced pricing information for eligible patients, including commercial-insurance savings and self-pay options. Because pharmaceutical prices, insurance coverage and eligibility can change, patients should verify current pricing through official sources before making treatment decisions.
How Much Does Foundayo Cost?
The Lilly announcement reported:
- Commercially insured eligible patients may pay as little as $25 per month with the Foundayo savings card.
- Self-pay pricing was announced starting at $149 per month for the lowest dose.
- Certain eligible Medicare Part D patients may have access at $50 per month, beginning as early as July 1, 2026, according to the announcement.
These figures should not be treated as universal prices.
Actual costs can depend on insurance coverage, eligibility, dose, pharmacy, savings programmes and other factors.
Foundayo vs Injectable GLP-1 Medicines
One of Foundayo’s most interesting characteristics is its oral formulation.
Many well-known GLP-1 medicines are administered by injection, while Foundayo is taken as a tablet.
This may matter for people who:
- Prefer oral medication.
- Do not want to administer injections.
- Want a simpler daily administration routine.
- Find injectable treatment inconvenient.
However, convenience does not automatically mean that Foundayo is the best treatment for everyone.
The appropriate medication depends on an individual’s medical history, treatment goals, other medicines, contraindications, tolerability and healthcare provider’s assessment.
Is Foundayo Better Than Mounjaro or Wegovy?
There is no simple answer.
Foundayo, Mounjaro and Wegovy belong to the broader group of medicines used for metabolic disease and weight management, but they are not identical medicines.
Direct comparisons should consider:
- Active ingredient
- Mechanism of action
- Oral versus injectable administration
- Clinical-trial population
- Duration of treatment
- Average weight loss
- Side-effect profile
- Contraindications
- Cost
- Insurance or NHS access
- Individual patient factors
It is therefore misleading to declare one medicine universally “better.”
A more accurate question is:
Which treatment is most appropriate for a particular patient?
That decision should be made with a healthcare professional.
What Makes Orforglipron Different?
Orforglipron has several features that distinguish it from many existing GLP-1 treatments.
Oral instead of injectable
Foundayo is administered as an oral tablet.
Small-molecule GLP-1 receptor agonist
It is described as a non-peptide, small-molecule GLP-1 receptor agonist.
Once-daily administration
The medicine is taken once daily.
Flexible administration
It can be taken with or without food.
Regulatory progress in the U.S. and UK
The FDA approved it in the U.S. in April 2026, while the UK MHRA authorised it in August 2026.
What Other Conditions Is Orforglipron Being Studied For?
The Lilly information states that, in addition to chronic weight management, orforglipron has been studied or is being studied for potential use in:
- Type 2 diabetes
- Obstructive sleep apnoea
- Osteoarthritis knee pain
- Hypertension
- Peripheral artery disease
- Stress urinary incontinence
However, readers should distinguish between an approved indication and an investigational indication.
A medicine being studied for a condition does not mean it has been approved for that condition.
Why the UK Approval Matters for the GLP-1 Market
The MHRA’s August 2026 decision is significant because the UK became the first European country to authorise orforglipron.
This could increase interest in oral GLP-1 medicines and provide another option for people who prefer tablets over injections.
The development is also relevant to the wider competition in the obesity-treatment market, where pharmaceutical companies are increasingly developing oral alternatives to injectable medicines.
What Should UK Patients Know Before Buying Foundayo Online?
The rapid growth of interest in GLP-1 medicines has also increased the risk of counterfeit, unauthorised or inappropriate products being sold online.
UK patients should be particularly cautious about websites offering:
- “No prescription” Foundayo
- Extremely cheap Foundayo
- Unverified orforglipron tablets
- Imported medicines without proper regulatory information
- Social-media weight-loss products claiming to contain GLP-1 medicines
A prescription medicine should be obtained through a legitimate, regulated healthcare and pharmacy pathway.
Do not purchase a medicine simply because a website claims it is “FDA approved” or “MHRA approved.”
Frequently Asked Questions About Foundayo
Is Foundayo FDA approved?
Yes. The FDA approved Foundayo (orforglipron) on April 1, 2026, for specified adults with obesity or overweight with a weight-related comorbidity, alongside diet and physical activity.
Is Foundayo approved in the UK?
Yes. The MHRA authorised orforglipron (Foundayo) on August 10, 2026, for weight management and type 2 diabetes in specified adults.
Is Foundayo a GLP-1 medicine?
Yes. Orforglipron is a GLP-1 receptor agonist. It is a small-molecule, non-peptide oral GLP-1 receptor agonist.
Is Foundayo a pill or injection?
Foundayo is an oral tablet.
How often is Foundayo taken?
It is taken once daily according to the healthcare provider’s instructions.
Can Foundayo be taken with food?
The U.S. medication information states that Foundayo can be taken with or without food.
How much weight did people lose in clinical trials?
In ATTAIN-1, participants who remained on the highest dose lost an average of 27.3 pounds, or 12.4%, after 72 weeks, compared with 0.9% with placebo.
Does everyone lose 12.4% of their weight?
No. The 12.4% figure is a clinical-trial average and should not be considered a guaranteed result for an individual.
Can Foundayo be taken with another GLP-1?
The U.S. medication information states that Foundayo should not be used with other GLP-1 receptor agonists.
Is Foundayo available on the NHS?
UK regulatory authorisation does not automatically mean universal NHS availability. NHS access depends on separate healthcare and commissioning decisions.
Is Foundayo available in the United States?
Following FDA approval, Lilly announced availability through LillyDirect and subsequent broader distribution through retail pharmacies and telehealth providers.
Final Takeaway
Foundayo (orforglipron) has become one of the most closely watched oral GLP-1 medicines for weight management in 2026.
The U.S. FDA approved Foundayo on April 1, 2026, while the UK MHRA authorised orforglipron on August 10, 2026. The UK became the first country in Europe to authorise the medicine.
Its key distinguishing feature is its once-daily oral formulation, which can be taken without the food-timing requirements associated with some other oral GLP-1 treatments.
Clinical data from the ATTAIN-1 trial showed an average weight reduction of 12.4% at 72 weeks at the highest dose among participants who remained on treatment, although individual results vary.
At the same time, Foundayo is a prescription medicine with important contraindications, warnings and potential adverse effects. It should be used only under appropriate medical supervision.
For people in the United States and United Kingdom, the FDA and MHRA authorisations make orforglipron particularly relevant as a new oral option in the rapidly evolving GLP-1 and obesity-treatment landscape.
Editorial Note
This article has been carefully researched and written by Deepak Rajput with a focus on accuracy, clarity, and evidence-based healthcare information.
